Outlook Therapeutics, Inc.

Outlook Therapeutics, Inc. is a late clinical-stage biopharmaceutical company focused on developing ONS-5010 \/ LYTENAVA™ (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, including wet AMD, DME and BRVO. If ONS-5010 is approved, Outlook Therapeutics expects to commercialize it as the first and only FDA-approved ophthalmic formulation of bevacizumab-vikg for use in treating retinal diseases in the United States, United Kingdom, Europe, Japan, and other markets. Outlook Therapeutics expects to file ONS-5010 with the U.S. FDA as a new BLA under the PHSA 351(a) regulatory pathway.

Founded in 2011, the company operates within the Biopharma, Biotechnology, and Pharmaceutical industries and is headquartered in the United States. The latest investment of $65.00M in Post-IPO Equity was made on 23 January 2024. Notable investors in this round include Altium Capital, Schonfeld Strategic Advisors, Woodline Partners, G. Sukhtian Business Development Holdings, SPA ANHAM Algeria, Great Point Partners, Velan Capital, Caligan Partners LP, Armistice Capital, Sphera Global Healthcare Fund, Syntone Ventures.